Premium
The effect of age on ranitidine pharmacokinetics
Author(s) -
Greene Douglas S,
Szego Peter L,
Anslow June A,
Hooper John W
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.43
Subject(s) - ranitidine , pharmacokinetics , plasma concentration , medicine , venous blood , gastroenterology , chemistry
Oral ranitidine was given to 68 healthy subjects between 18 and 75 years old at a dosage of 150 mg twice a day for seven doses. Fifteen subjects were 18 to 35 years old (group I), 19 subjects were 36 to 50 years old (group II), 19 subjects were 51 to 65 years old (group III), and 15 subjects were 66 to 75 years old (group IV). Venous blood samples were drawn and the AUC from 0 to 12 hours, the maximum plasma concentration, the time of the maximum plasma concentration, the minimum plasma concentration, and the elimination t ½ were determined. When groups III or IV were compared with groups I or II, significant (P < 0.05) increases were seen in the AUC(0–12) (42% and 50%), the maximum plasma concentration (36% and 41%), the minimum plasma concentration (91% and 85%), and the elimination t ½ (29% and 33%). Positive linear correlations were found when the AUC(0–12) (r = 0.68; P < 0.01), the maximum plasma concentration (r = 0.34; P < 0.01), the minimum plasma concentration (r = 0.55; P < 0.01), and the elimination t ½ (r = 0.46; P < 0.01) were regressed with age. Our results suggest that it may be appropriate to consider dosage adjustments for patients over 50 years of age who take ranitidine. Clinical Pharmacology and Therapeutics (1986) 39, 300–305; doi: 10.1038/clpt.1986.43